Clinical trial
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT02159495 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- December 15, 2015
- Completion date
- July 14, 2027
- Enrollment
- 31 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute biphenotypic leukemia, acute myeloid leukemia, adult acute lymphoblastic leukemia, adult acute myeloid leukemia in remission, blastic plasmacytoid dendritic cell neoplasm, early relapse of acute myeloid leukemia, interleukin-3 receptor subunit alpha positive, late relapse of acute myeloid leukemia, minimal residual disease, recurrent adult acute myeloid leukemia, refractory acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia